Insulin constitutes a principal evolutionarily conserved hormonal axis for maintaining glucose homeostasis 1-3 ; dysregulation of this axis causes diabetes 2,4 . PGC-1a (peroxisome-proliferator-activated receptorc coactivator-1a) links insulin signalling to the expression of glucose and lipid metabolic genes [5] [6] [7] . The histone acetyltransferase GCN5 (general control non-repressed protein 5) acetylates PGC-1a and suppresses its transcriptional activity, whereas sirtuin 1 deacetylates and activates PGC-1a 8, 9 . Although insulin is a mitogenic signal in proliferative cells 10,11 , whether components of the cell cycle machinery contribute to its metabolic action is poorly understood. Here we report that in mice insulin activates cyclin D1-cyclin-dependent kinase 4 (Cdk4), which, in turn, increases GCN5 acetyltransferase activity and suppresses hepatic glucose production independently of cell cycle progression. Through a cell-based high-throughput chemical screen, we identify a Cdk4 inhibitor that potently decreases PGC-1a acetylation. Insulin/GSK-3b (glycogen synthase kinase 3-beta) signalling induces cyclin D1 protein stability by sequestering cyclin D1 in the nucleus. In parallel, dietary amino acids increase hepatic cyclin D1 messenger RNA transcripts. Activated cyclin D1-Cdk4 kinase phosphorylates and activates GCN5, which then acetylates and inhibits PGC-1a activity on gluconeogenic genes. Loss of hepatic cyclin D1 results in increased gluconeogenesis and hyperglycaemia. In diabetic models, cyclin D1-Cdk4 is chronically elevated and refractory to fasting/feeding transitions; nevertheless further activation of this kinase normalizes glycaemia. Our findings show that insulin uses components of the cell cycle machinery in post-mitotic cells to control glucose homeostasis independently of cell division.
Insulin constitutes a principal evolutionarily conserved hormonal axis for maintaining glucose homeostasis [1] [2] [3] ; dysregulation of this axis causes diabetes 2, 4 . PGC-1a (peroxisome-proliferator-activated receptorc coactivator-1a) links insulin signalling to the expression of glucose and lipid metabolic genes [5] [6] [7] . The histone acetyltransferase GCN5 (general control non-repressed protein 5) acetylates PGC-1a and suppresses its transcriptional activity, whereas sirtuin 1 deacetylates and activates PGC-1a 8, 9 . Although insulin is a mitogenic signal in proliferative cells 10, 11 , whether components of the cell cycle machinery contribute to its metabolic action is poorly understood. Here we report that in mice insulin activates cyclin D1-cyclin-dependent kinase 4 (Cdk4), which, in turn, increases GCN5 acetyltransferase activity and suppresses hepatic glucose production independently of cell cycle progression. Through a cell-based high-throughput chemical screen, we identify a Cdk4 inhibitor that potently decreases PGC-1a acetylation. Insulin/GSK-3b (glycogen synthase kinase 3-beta) signalling induces cyclin D1 protein stability by sequestering cyclin D1 in the nucleus. In parallel, dietary amino acids increase hepatic cyclin D1 messenger RNA transcripts. Activated cyclin D1-Cdk4 kinase phosphorylates and activates GCN5, which then acetylates and inhibits PGC-1a activity on gluconeogenic genes. Loss of hepatic cyclin D1 results in increased gluconeogenesis and hyperglycaemia. In diabetic models, cyclin D1-Cdk4 is chronically elevated and refractory to fasting/feeding transitions; nevertheless further activation of this kinase normalizes glycaemia. Our findings show that insulin uses components of the cell cycle machinery in post-mitotic cells to control glucose homeostasis independently of cell division.
To discover new factors that can regulate PGC-1a activity through its acetylation status, a high-throughput enzyme-linked immunoassay was designed to monitor specifically and quantitatively the amount of PGC-1a acetylation in U-2OS cells (Extended Data Fig. 1a ). A library of 1,600 compounds, including bioactive and natural compounds, was screened ( Fig. 1a) . Interestingly, the compound with the highest z score for PGC-1a deacetylation was fascaplysin, a known Cdk4 inhibitor 12 (Extended Data Fig. 1b ). Cdk4 regulates G1 to S phase transition and its kinase activity is dependent on its binding to one of the three D-type cyclins including cyclin D1 (ref. 13) . We therefore investigated the effect of this cell cycle complex on PGC-1a acetylation and function, in connection with nutrient and insulin metabolic actions.
First, we calculated a half-maximum inhibitory concentration (IC 50 ) of 0.7 mM for fascaplysin-induced PGC-1a deaceylation, which is similar to its IC 50 for Cdk4 inhibition (Extended Data Fig. 2a ). Fascaplysininduced PGC-1a deacetylation overlapped with retinoblastoma protein (Rb) dephosphorylation, a well-characterized Cdk4 substrate 14 (Fig. 1b) . PD 0332991, the most specific Cdk4 inhibitor available 15 , led to a similar decrease of PGC-1a acetylation ( Fig. 1c and Extended Data Fig. 2b ). Furthermore, Cdk4 depletion through transient short hairpin RNA (shRNA) transfection had the same effect as chemical inhibitors, confirming that Cdk4 activity controls PGC-1a acetylation levels ( Fig. 1d and Extended Data Fig. 2c ).
Because Cdk4 inhibitor-induced PGC-1a deacetylation was not affected when sirtuin 1 (SIRT1) or HDAC class I/II were inhibited (Extended Data Fig. 2d ), we tested whether cyclin D1-Cdk4 regulates PGC-1a acetylation through GCN5, the principal PGC-1a acetyltransferase. Indeed, knockdown of Gcn5 significantly blunted fascaplysin-induced PGC-1a deacetylation (Fig. 1e ). In contrast, PCAF-mediated acetylation was not affected by fascaplysin, further suggesting that Cdk4 inhibition modulates PGC-1a acetylation through GCN5 (Extended Data Fig. 2e ).
In vitro catalytic activity of GCN5 immunoprecipitated from cells treated with fascaplysin was reduced by 50% relative to vehicle control ( Fig. 1f ). We observed physical interaction between ectopically expressed or endogenous Cdk4 and GCN5, suggesting that Cdk4 could regulate GCN5 activity by direct phosphorylation (Fig. 1g and Extended Data Fig. 2f ). Cyclin D1-Cdk4 kinase directly phosphorylated GCN5 in vitro and its phosphorylation was inhibited by fascaplysin ( Fig. 1h and Extended Data Fig. 2g ). Systematic mutagenesis showed two phosphorylation sites, T272 and S372, located in the conserved PCAF domain of GCN5. Alanine substitutions of these two sites ('GCN5 AA') ablated GCN5 phosphorylation by cyclin D1-Cdk4 in vitro, and reduced PGC-1a acetylation (Fig. 1i, 1j and Extended Data Fig. 2h , i). Compared with GCN5 wild type, in vitro catalytic activity of GCN5 AA was decreased, but remained insensitive to fascaplysin (Fig. 1k ). Cdk4 phosphorylation on GCN5 augmented acetyltransferase catalytic activity by increasing maximal velocity (V max ), whereas the Michaelis-Menten constant (K m ) for acetyl-CoA binding was unaffected ( Fig. 1k ). Because GCN5 functions as a complex with subunits important for its activity 16 , its phosphorylation by Cdk4 could modulate interaction between GCN5 and subunits. We found one subunit, PAF65-b, interacting less with GCN5 AA compared with GCN5 wild type, when tested with modestly overexpressed GCN5, where PGC-1a acetylation was not saturated (Extended Data Fig. 2j, k) . Taken together, these results indicate that cyclin D1-Cdk4 regulates PGC-1a acetylation through the direct phosphorylation and activation of GCN5 acetyltransferase activity.
Because PGC-1a acetylation is tightly linked with its co-transcriptional activity 8, 9, 17 , we investigated whether cyclin D1-Cdk4 could modulate the gluconeogenic target genes of PGC-1a. To study cyclin D1-Cdk4 kinase effects in a PGC-1a mediated manner, we induced PGC-1a in primary hepatocytes by adenoviral overexpression or forskolin addition (Extended Data Fig. 3a ). In primary hepatocytes, chemical inhibition of Cdk4 significantly increased gluconeogenic genes and glucose production, consistent with reduced PGC-1a acetylation ( Fig. 2a -c and Extended Data Fig. 3b ). Cdk4 depletion produced similar effects ( Fig. 2d-f and Extended Data Fig. 3c ). Conversely, induction of CKD4 activity by cyclin D1 wildtype overexpression or cyclin D1 T286A mutant, a hyperactive mutant allele spared from proteasomal degradation 18 , but not cyclin D1 K112E (a mutant that cannot activate Cdk4 kinase activity 19 ), suppressed gluconeogenic genes and glucose production, corresponding with PGC-1a acetylation changes ( Fig. 2g -i and Extended Data Fig. 3d ).
Because cyclin D1-Cdk4 can phosphorylate other regulatory components of gluconeogenic pathway 20 (Extended Data Fig. 3e ), we examined whether cyclin D1-Cdk4 kinase modulates glucose production through PGC-1a and GCN5. As expected, the induction of gluconeogenic genes by Cdk4 inhibition was completely blunted when PGC-1a was stably knocked down in liver cells (Extended Data Fig. 3f ). Also, Cdk4 knockdown did not increase glucose production and gluconeogenic gene expression in GCN5 depleted hepatocytes ( Fig. 2j and Extended Data Fig. 3g ). GCN5 AA had a marginal ability to suppress hepatic gluconeogenesis compared with GCN5 wild type, and showed no significant changes when combined with Cdk4 inhibition ( Fig. 2k and Extended Data Fig. 3h ). Together, these results strongly suggest that the effects of cyclin D1-Cdk4 on gluconeogenesis are mediated by the GCN5-PGC-1a complex.
We examined whether liver gluconeogenesis was altered when cyclin D1-Cdk4 kinase activity was manipulated in whole animals. When PD 0332991 was administered to re-fed mice, it increased Pck1 expression and glycaemia without changing circulating insulin levels (Fig. 2l , m and Extended Data Fig. 3i , j). In contrast, hepatic cyclin D1 T286A expression significantly repressed fasting gluconeogenic genes, glycaemia and hepatic capacity to produce glucose as assessed by a pyruvate tolerance test ( Fig. 2n -p and Extended Data Fig. 3k ). We confirmed that PD 03322991 or cyclin D1 T286A adenoviral administration produced those physiological changes without causing liver toxicity (Extended Data Fig. 4a, b ). Collectively, these data indicate that changes in hepatic cyclin D1-Cdk4 activity are sufficient to control hepatic gluconeogenesis and wholebody glucose homeostasis.
Next, we investigated whether cyclin D1-Cdk4 complex is regulated under nutritional and hormonal changes. In spite of parenchymal hepatocytes being post-mitotic, hepatic protein and messenger RNA (mRNA) expression of cyclin D1 were significantly increased upon 4 h re-feeding, which was not a strain-specific phenomenon (Fig. 3a, b and Extended Data Fig. 5a, b ). This induction of cyclin D1 corresponded with elevated cyclin D1-Cdk4 activity, as observed by increases of Rb, GCN5 phosphorylation and elevated kinase activity of immunoprecipitated Cdk4 upon re-feeding (Fig. 3b , c and Extended Data Fig. 5c ). Interestingly, cyclin D1 expression was regulated upon re-feeding only in liver, and Cdk4 inhibitor administration altered PGC-1a target genes only in liver and white adipose tissue (Extended Data Fig. 5d , e). Although Cdk4 regulates glucose metabolism in other tissues than liver, it is unknown whether this regulation is dependent on PGC-1a 21 .
Cyclin D1-Cdk4 activity increased upon re-feeding was uncoupled from cell cycle progression. Known cell division markers did not change upon re-feeding (Extended Data Fig. 5f ). Consistently, we found no difference in hepatocyte ploidy profile, Ki-67 expression levels and 5bromodeoxyuridine (BrdU) incorporation between the livers of fasted and re-fed mice (Fig. 3d , e and Extended Data Fig. 5g ). Alteration of cyclin D1-Cdk4 activity in liver by hepatic overexpression of cyclin D1 T286A or by a pharmacological inhibition caused no changes in cell cycle progression during fasting and re-feeding, as analysed by hepatic ploidy and Ki-67 expression (Extended Data Fig. 5h-j) .
GSK-3b, active during fasting and inactive during re-feeding owing to its phosphorylation by insulin-AKT signalling, negatively regulates cyclin D1 through phosphorylation of T286, causing nuclear exclusion of cyclin D1 and proteasomal degradation 18, 22 . We considered that insulin stimulation and subsequent inactivation of GSK-3b allow cyclin D1 to form an active complex with Cdk4, promoting PGC-1a acetylation. Insulin or two GSK-3b inhibitors increased nuclear cyclin D1 protein when tested in an overexpressed or endogenous manner ( Fig. 3f and Extended Data Fig. 5k ). This increase correlated with elevated PGC-1a acetylation and a significant reduction of gluconeogenic genes ( Fig. 3g and Extended Data Fig. 5l ). In accordance, insulin increased Cdk4mediated GCN5 phosphorylation ( Fig. 3h ). Interestingly, we found that amino acids, but not insulin, increased cyclin D1 mRNA expression in primary hepatocytes (Extended Data Fig. 5m-o) . To test if amino acids could be dietary components promoting cyclin D1 mRNA in liver, mice were fed with empty calorie, glucose only or glucose and amino-acid diets for 4 h. A significant cyclin D1 mRNA induction was observed only 
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when amino acids were added to the diet (Fig. 3i ). These results indicate that amino acids contribute to the fed response along with insulin signalling to enhance cyclin D1 levels during re-feeding.
To test if cyclin D1-Cdk4 complex constitutes an important axis of the nutrient and insulin signalling to regulate glucose metabolism, we generated liver-specific cyclin D1 knockout ('D1 LKO') mice by crossing mice expressing a floxed cyclin D1 allele 23 with albumin-Cre-expressing mice 24 . Cyclin D1 deletion in liver did not interfere with liver development and caused no compensatory increases on other cyclins (Extended Data Fig. 5p , q). D1 LKO mice had similar gluconeogenic gene expression and glycaemia during fasting compared with wild-type mice, consistent with Cdk4 inactivation due to the absence of cyclin D1 (Fig. 3j, k) . However, in the re-fed state, D1 LKO mice showed a significant increase in gluconeogenic genes and glycaemia compared with wild-type mice whereas induction of Rb phosphorylation and PGC-1a acetylation upon re-feeding were lacking (Fig. 3l , m and Extended Data Fig. 5r , s). Cdk4 inhibitor failed to increase gluconeogenic genes and glycaemia further in D1 LKO mice, suggesting cyclin D1 in liver mediates metabolic effects caused by Cdk4 inhibition (Extended Data Fig. 5t, u) . Primary hepatocytes isolated from D1 LKO mice had increased gluconeogenic gene expression and higher glucose production than wild-type hepatocytes (Extended Data Fig. 5v , w). Consistent with elevated re-feeding blood glucose levels, D1 LKO mice showed moderate, yet significant, insulin and glucose intolerance, further indicating that cyclin D1-Cdk4 mediates, at least in part, insulin action in liver ( Fig. 3n , o). When taken in aggregate, our findings indicate that insulin suppresses hepatic gluconeogenesis during re-feeding, in part by activating cyclin D1-Cdk4 complex to suppress PGC-1a activity.
Lastly, we investigated whether cyclin D1-Cdk4 activity was altered in diabetic mice. In the livers of fasted Lepr db/db mice, basal phosphorylations of AKT and its downstream targets were elevated, consistent with the hyperinsulinaemia of db/db mice ( Fig. 4a ). Accordingly, db/db mice had elevated fasted levels of cyclin D1 and phosphorylation of Rb, comparable to re-fed db/1 mice. In db/db mice, gluconeogenic genes and insulin signalling were refractory to fasting/re-feeding transitions, indicating an uncoupling of insulin signalling and its repressive effects on gluconeogenic programming ( Fig. 4a and Extended Data Fig. 6a ). We observed similar chronic elevations of cyclin D1 and insulin signalling impairment in mice fed a high-fat diet (Extended Data Fig. 6b ). In accordance with chronic elevation of cyclin D1 in diabetic mice, phosphorylation of GCN5 remained higher, refractory to fasting/re-feeding transitions in diabetic compared with control mice (Extended Data Fig. 6c, d) . These results suggest that in insulin-resistant mice compensatory hyperinsulinaemia maintains a chronically active cyclin D1-Cdk4 complex that is not sufficient to counteract increased gluconeogenesis. Hyperinsulinaemia might explain other studies showing different activities of insulin signalling in fasted diabetic animals 25, 26 .
We examined whether hyperactivation of cyclin D1-Cdk4 complex in db/db mice could alleviate hyperglycaemia. Hepatic overexpression of cyclin D1 T286A in db/db mice reduced gluconeogenic genes and glycaemia to db/1 mouse levels, whereas cyclin D1 K112E caused only minor suppressions of those parameters (Fig. 4b, c and Extended Data Fig. 6e ). A similar pattern was observed in mice fed a high-fat diet (Extended Data Fig. 6f -h). We confirmed that cyclin D1 T286A overexpression in db/db mice indeed repressed hepatic glucose production by using hyperinsulinemic-euglycemic clamp experiments ( Fig. 4d-h) .
Our studies support a regulatory model in which insulin facilitates the formation of an active cyclin D1-Cdk4 complex that subsequently suppresses gluconeogenesis, in part by decreasing PGC-1a activity through hepatocytes and whole animals. a, b, PD 0332991 increases gluconeogenic gene expression and glucose production (a: one-way analysis of variance (ANOVA) with Tukey post-test, n 5 3, b: two-tailed unpaired t-test, n 5 8). c, PGC-1a acetylation is decreased by PD 0332991 treatment. d, e, Cdk4 knockdown increases gluconeogenic gene expression and glucose production (d: one-way ANOVA with Tukey post-test, n 5 6, e: two-tailed unpaired t-test, n 5 6). f, PGC-1a acetylation is decreased upon Cdk4 deletion. g, h, Cyclin D1 wild-type decreases gluconeogenic gene expression, and cyclin D1 wild-type and cyclin D1 T286A, but not cyclin D1 K112E, repress glucose production (g: one-way ANOVA with Tukey post-test, n 5 3/green fluorescent protein (GFP), PGC-1a, n 5 6/cyclin D1 WT and KE, h: one-way ANOVA with Dunnett post-test, n 5 8). i, Overexpression of cyclin D1 wild-type (WT) and T286A (TA), but not cyclin D1 K112E (KE), induces PGC-1a acetylation. j, Gcn5 knockdown blunts the increase of glucose production by Cdk4 knockdown (two-tailed unpaired t-test, n 5 8). k, PD 0332991 increases glucose production with GCN5 wild type (WT), but not with GCN5 T272A/ S372A (AA) (one-way ANOVA with Newman-Keuls post-test, n 5 8). l, m, PD 0332991 administration increases Pck1 gene expression and glycaemia in mice (two-tailed unpaired t-test, n 5 18/vehicle, n 5 17/PD 0332991). n, o, Gluconeogenic gene expression and glycaemia are reduced by cyclin D1 T286A overexpression in liver (two-tailed unpaired t-test, n 5 10/GFP, n 5 9/D1 T286A). p, Cyclin D1 T286A overexpression in liver decreases hepatic glucose production capacity assessed by pyruvate tolerance test (two-tailed unpaired t-test, n 5 20/GFP, n 5 24/D1 T286A; AUC, area under curve). All cells were infected with PGC-1a adenovirus for glucose production assays. Statistical significance is represented by asterisks corresponding to *P , 0.05, **P , 0.01 and ***P , 0.001. Data are shown as mean 6 s.e.m. Figure 3 | Cyclin D1-Cdk4 is regulated by insulin/GSK-3b, and hepatic cyclin D1 deletion causes increased gluconeogenesis and glycaemia upon refeeding. a, Cyclin D1 gene expression is increased during re-feeding (one-way ANOVA with Tukey post-test, n 5 3/fast and10 h re-fed, n 5 4/4 h re-fed). b, Cyclin D1 protein and Rb phosphorylation are induced upon re-feeding (N, nuclear, and C, cytoplasmic, liver extracts). c, Phosphorylation of GCN5 is increased upon re-feeding. GCN5 was immunoprecipitated using anti-phosphoS*P (pS*P) antibody from livers infected with GFP or GCN5 adenovirus. d, Hepatocyte ploidy does not change upon fasting and re-feeding (n 5 5). e, Ki-67 staining in liver shows no differences upon fasting and refeeding. Small intestine was used as a positive control. f, Nuclear cyclin D1 protein level is increased upon insulin and GSK-3b inhibitor treatment in primary hepatocytes. All cells were infected with cyclin D1 wild-type adenovirus. g, Insulin and GSK-3b inhibitors suppress gluconeogenic gene expression. All cells were infected with PGC-1a adenovirus (one-way ANOVA with Tukey post-test, n 5 6). h, Phosphorylation of GCN5 is induced by insulin and blunted by PD 0332991 treatment. GCN5 was overexpressed whereas GFP was used as a negative control. i, Cyclin D1 is transcriptionally induced by dietary intake of amino acids. Mice were fasted overnight or re-fed 4 h with chow diet, empty calorie, glucose or glucose and amino-acid diet (one-way ANOVA with Tukey post-test, n 5 5). j, k, Liver-specific cyclin D1 LKO mice show no differences on gluconeogenic gene expression and glycaemia during fasting. l, m, D1 LKO mice show increased gluconeogenic gene expression and glycaemia upon 4 h re-feeding (one-way ANOVA with Tukey post-test, combined four cohorts of n 5 3/fasting, n 5 5/re-feeding). n, D1 LKO mice show mild glucose intolerance (two-way ANOVA, multiple comparison, n 5 11/WT1, n 5 7/WT2, n 5 10/D1 LKO). o, D1 LKO mice show mild insulin intolerance (two-way ANOVA, significant interaction, multiple comparison, n 5 10/WT1, n 5 7/WT2, n 5 9/D1 LKO). Statistical significance is represented by asterisks corresponding to *P , 0.05, **P , 0.01, ***P , 0.001. Data are shown as mean 6 s.e.m. 
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GCN5-mediated acetylation (Extended Data Fig. 6i ). Under type 2 diabetic conditions, cyclin D1 protein levels are dysregulated owing to hyperinsulinaemia and insulin resistance, which contributes to its inability to repress gluconeogenesis fully during the fed state. In addition, cyclin D1 is also controlled at the transcriptional level by dietary intake of amino acids, further contributing to insulin's action, although the mechanisms are currently unknown. Despite the functional activation of cyclin D1-Cdk4 during re-feeding, hepatocytes undergo no cell cycle progression. Interestingly, genome-wide association studies have showed that mutations of CDKN2A, a Cdk4 inhibitor, are significantly correlated with a high risk of type 2 diabetes 27 . Combined with the role of cyclin D1-Cdk4 in b-islet pancreatic cell proliferation and the involvement of its target, E2F1, in oxidative metabolism 28, 29 , induction of gluconeogenesis in liver could predict the tendency of hyperglycaemia in cancer patients treated with Cdk4 inhibitors 30 . Future studies will address the metabolic functions of cell cycle components in different tissues and their use as therapeutic targets in metabolic diseases.
METHODS SUMMARY
The chemical screen was performed with a U-2OS cell line as described in Extended Data Fig. 1a . Immunoprecipitated GCN5 from cells infected with GCN5 adenoviruses was used for in vitro acetyltransferase activity assay. Glutathione S-transferase (GST)-cyclin D1-Cdk4, GST-Rb and 6 3 His-GCN5 recombinant proteins were purchased whereas others were generated in the laboratory. Glucose levels in culture medium were measured with primary hepatocytes overexpressing PGC-1a. All animal studies were performed with 8-to 10-week-old male C57BL/6 mice unless indicated otherwise. PD 0332991 (150 mg kg 21 , pH 4) was administered by oral gavage. Adenoviruses were delivered by tail-vein injection with dosages of 1.5 3 10 9 to 2.0 3 10 9 infectious particles per animal. Pyruvate tolerance test was performed by intraperitoneal injection of pyruvate (2 g kg 21 ) to overnight fasted mice whereas glucose tolerance (1 g kg 21 ) and insulin tolerance tests (0.75 U kg 21 , diluted in PBS) were performed with mice fasted for 6 h. Diets containing empty calorie, glucose or glucose and amino acids were formulated in the laboratory. High-fat diet (60 kcal%) was administered to animals for 3 months before experiments. Detailed experimental procedures can be found in Methods.
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper.
METHODS
Animal experiments. Eight-to 10-week-old male BALB/c mice and 8-to 10-weekold male C57BL/6 mice were purchased from Taconic Farms. Ten-week-old male BKS.Cg-Dock7 m 1/1 Lepr db /J heterozygous (db/1) and homozygous (db/db) mice were from Jackson Laboratory. After a delivery of mice to the animal facility, a 1-week acclimation period was given before experiments. No randomization and blind techniques were applied in this study. Liver-specific cyclin D1 LKO mice were generated by crossing mice expressing a floxed cyclin D1 allele (mixed background between 129/SvJ and C57BL/6 and backcrossed to C57BL/6 for five times) 23 with albumin-Cre-expressing mice 24 . High fat diet (60 kcal%) (D12492i) and its control diet (D12450J) were administered to animals for 3 months before experiments. PD 0332991 was dissolved in 20 mM sodium lactate solution made at pH 4.0. The compound (150 mg kg 21 ) or buffer solution was given to each mouse once per day by oral gavage. After two consecutive administrations, all mice were killed upon 4 h re-feeding followed by overnight fasting, except the administration was reduced to once in the experiments with D1 LKO mice. To overexpress cyclin D1 T286A or K112E in liver, adenoviruses were injected through the tail vein and GFP adenovirus was used as a negative control (all constructs with 1.5 3 10 9 infectious particles per lean mouse and 2.0 3 10 9 per obese mouse). All mice were killed after 4 days of injection followed by overnight fasting unless indicated otherwise (the fasting started 1 h after the dark-cycle initiated in the facility). Before being killed, all mice were tail bled to measure glycaemia using Precision Xtra from Abbott Diabetes Care. Upon collection, livers were removed and snap frozen in liquid nitrogen until processed.
For BrdU incorporation, 100 mg g 21 body weight was given intraperitoneally 16 h before collection. For RNA extraction from pancreas, we followed the modified protocol previously reported 31 and the quality of RNA samples was verified by 28S/18S presence using 1% agarose gel electrophoresis. For diet experiments, 3% agar was autoclaved and mixed with glucose (1.8 kcal g 21 ), amino acids (0.9 kcal g 21 ) or both. Each amino acid was weighed and mixed as LabDiet (5001) formula indicates. For the pyruvate tolerance test, pyruvate (2 g kg 21 , dissolved in PBS) was injected intraperitoneally to overnight-fasted mice, 4 days after adenoviral injections. For the glucose tolerance and insulin tolerance tests, mice were fasted for 6 h before injection and glucose (1 g kg 21 dissolved in PBS) and insulin (0.75 U kg 21 diluted in PBS) were delivered by intraperitoneal injection. Glycaemia was monitored by tail-bleeding every 15-20 min; if hypoglycaemia caused by insulin injection was observed, 1 g kg 21 glucose was injected and the mice was exempted from experiment. All animal experiments were designed and conducted by following the Dana-Farber's Institutional Animal Care and Use Committee. Insulin and serum biochemistry measurement. Upon being killed, serum samples were gathered from blood collected by cardiac puncture. Insulin was measured with Ultra Sensitive Mouse Insulin ELISA Kit (Crystal Chem, 90080). All kits used to measure serum biochemistry including alanine transaminase (EALT-100), aspartate transaminase (EASTR-100), lactate dehydrogenase (DLDH-100), creatine kinase (ECPK-100) and total bilirubin (DIBR-100) were purchased from Bioassay Systems. High-throughput chemical screening. U-2OS human osteosarcoma cells were infected with Flag-tagged PGC-1a and GCN5 expressing adenovirus and were split to 384-well plates. The chemical compounds were added to the cells and incubated overnight. Cells were collected and lysates were transferred to enzyme-linked immunosorbent assay (ELISA) plates (Nunc, 460372) coated with M2 FLAG-antibody (Sigma, F1804) to immunoprecipitate PGC-1a. The plates were washed with PBST buffer, and acetylated-lysine antibody (Cell Signaling, 9441) was added to detect the acetylation level of PGC-1a. After primary antibody incubation, horseradish peroxidase (HRP)-IgG-Rabbit antibody (Jackson Immuno Research, 711035152) was added as a secondary antibody. A plate reader recorded the signal after incubating the plates with HRP-reacting ELISA substrate (Thermo Scientific, 37069) to generate chemiluminescence at 425 nm. Further details for the screening conditions are available upon request. Adenoviruses, constructs and recombinant information. All adenoviruses were generated by using the pAdTrack/pAdEasy system and amplified in HEK293A cells. Adenoviruses were purified by caesium chloride gradient centrifugation and dialysed in Tris-HCl buffer made at pH 8 before use. Flag-HA-PGC-1a (mouse) and Flag-GCN5 (mouse) adenoviruses were made as previously described 8, 9 . Flag-cyclin D1 wild-type and K112E (mouse) adenoviruses were generated by subcloning from reported constructs given by P. Sicinski. Flag-cyclin D1 T286A (human) was subcloned from a construct obtained from Addgene deposited by B. Zetter. Adenovirus with short-hairpin RNA was driven by a U6 promoter and subcloned from a pLKO.1 vector. pLKO.1 vector with shRNA against mouse Cdk4 construct targeting 59-CCTAGCTAGAATCTACAGCTA-39 was obtained from the Dana-Farber RNAi Screening Facility. pLKO.1 vectors with shRNA containing scrambled sequence 59-CAACAAGATGAAGAGCACCAA-39 were used to generate a control virus.
The sequence of shGcn5 against GCN5 was previously used and described 9 . pLKO.1 vectors with various shRNAs against human Cdk4 were obtained from the Dana-Farber RNAi Screening Facility with the following sequences; shCdk4#1 59-GACACTGAGAGGGCAATCTTT-39, shCdk4#2 59-GTGGAGTGTTGGCT GTATCTT-39, shCdk4#3 59-CATGCCAATTGCATCGTTCAC-39, shCdk4#4 59-GAGATTACTTTGCTGCCTTAA-39, and shCdk4#5 59-GTTCTTCTGCAGTCC ACATAT-39. Cell lines and primary hepatocytes cultures. HEK293A, U-2OS, HepG2 cells were purchased from ATCC (CRL-1573, HTB-96 and HB-8065) and maintained in DMEM containing 10% FBS under 5% CO 2 condition. All transformed cells were tested negative for mycoplasma using a PCR mycoplasma detection kit (Takara Bio, 6601). All constructs were transfected using Polyfect (Qiagen, 301105) and cells were collected after 48 h or 72 h of transfection. Medium was changed every day as well as 3 h before collection. For U-2OS cells, 1 mM Cdk4 inhibitors were added 8 h before collection. Dimethylsulphoxide (DMSO) was used as a negative control treatment for all chemical treatments used in this study. Lentiviral shRNAs for shScr and Pgc1a were produced by transfecting HEK293A cells with pLKO.1 shScr and shPgc1a; the sequences of shRNAs have been reported previously 32 . Control and PGC-1a stably knocked down HepG2 cells were generated by infecting cells with lentiviral particles and selected with puromycin for a week.
Primary hepatocytes were isolated from 8-to 10-week-old male BALB/c mice by perfusion with liver digest medium (Invitrogen, 17703-034) followed by 70 mm mesh filtration. Percoll (Sigma, P7828) gradient centrifugation allowed primary hepatocytes isolation from other cell types and debris. On six-well plates, 4 3 10 5 cells per well were seeded in plating medium (DMEM with 10% FBS, 2 mM sodium pyruvate, 1% penicillin/streptomycin, 1 mM dexamethasone, and 100 nM insulin). After 3 h of seeding, the medium was changed and incubated overnight in maintenance medium (DMEM, 0.2% BSA, 2 mM sodium pyruvate, 1% penicillin/streptomycin, 0.1 mM dexamethasone, and 1 nM insulin). To infect cells with adenovirus, 3 3 10 6 to 8 3 10 6 infectious particles per well were added to cells for 4 h. Cells were collected within 48 h after infection and medium was changed everyday as well as 3 h before collection. Cdk4 inhibitors and GSK-3b inhibitors (1 mM) were added overnight whereas 200 nM insulin was added 1.5 h before collection. When necessary, the medium was changed to starvation medium (DMEM, 0.2% BSA, 2 mM sodium pyruvate, and 1% penicillin/streptomycin) for 3 h and cells were stimulated with 10 mM forskolin for an extra 1.5 h. When glucose production was measured, cells were incubated in starvation medium for 2 h followed by incubation for 3 h in glucose-free medium (phenol-red/glucose free DMEM, 0.2% BSA, 2 mM sodium pyruvate and 20 mM sodium lactate). The glucose level in the medium was measured by glucose assay kit from Bioassay Systems (EBGL-100) following the manufacturer's instructions. For amino-acid addition, primary hepatocytes were incubated overnight with amino-acid-free medium (Earl's balanced salt solution, 25 mM glucose, 2 mM sodium pyruvate, 1% penicillin/streptomycin, BME vitamin mix and 0.2% fatty-acid-free BSA). Cells were collected after incubation for 4 h with 4 mM HEPES-KOH pH 7.4 buffer, minimum essential medium (MEM) amino acids or non-essential amino acids. Cell lysis, immunoprecipitation and western blot analysis. In the case of PGC-1a acetylation detection from PGC-1a overexpressed cells, cells were collected in RIPA buffer (containing protease inhibitor cocktail, 5 mM NaF, 5 mM glycerate-2phosphate, 20 mM nicotinamide, 1 mM DTT and 1 mM trichostatin A). Flag-HA-PGC-1a was immunoprecipitated with Flag-beads (Sigma A2220). For endogenous PGC-1a immunoprecipitation, cells or pulverized tissues were incubated with buffer A to obtain nuclear pellets (buffer A: 10 mM HEPES-KOH pH 7.9, 10 mM KCl, 1.5 mM MgCl 2 , 0.25% Igepal and reagents mentioned above). Once cytoplasmic fractions were removed, nuclear pellets were lysed in RIPA buffer without SDS. From the lysate, endogenous PGC-1a was immunoprecipitated by anti-PGC-1a antibody (Santa Cruz Biotechnology sc-13067) coupled with Dynabeads protein A (GE Lifescience 1001D). For endogenous co-immunoprecipitation experiments, proteins from nuclei were extracted in CHAPS based lysis buffer (10 mM HEPES-KOH pH 7.4, 150 mM NaCl, 0.5% Igepal, 0.3% CHAPS, 10% glycerol and reagents mentioned above). The lysate was pre-cleared with protein A (GE Lifescience 17-0780-01), and anti-Cdk4 antibody (Santa Cruz Biotechnology sc-260) was added to the immunoprecipitate. GCN5 pull-down with anti-phospho-S*P antibody was performed with whole-cell lysates extracted with RIPA buffer without SDS followed by protein A pre-clearing and incubation with anti-phospho-S*P antibody (Cell Signaling 2325). All immunoprecipitated samples were washed at least four times with lysis buffer. For all endogenous immunoprecipitation experiments, rabbit IgG antibody was used as a negative control.
The following antibodies were used for western blot analysis: anti-PGC-1a (sc-13067), anti-Cdk4 (sc-260) and anti-cyclin D1 (sc-450) from Santa Cruz Biotechnology; anti-acetylated-lysine (9441), anti-GCN5 (3305), anti-pSer780 Rb (3590 or 8180), anti-Rb (9313), anti-cyclin D1 (2978), anti-pThr308 AKT (2965), anti-pSer473 AKT (4060), anti-AKT (9272), anti-pSer9 GSK-3b (9323) and anti-GSK-3b (9315) from Cell Signaling; anti-Lamin B (ab16048) and anti-Rabbit IgG (ab37415) from Abcam; anti-tubulin (05-661) from Millipore; anti-Flag (A8592) and anti-bactin (A2228) from Sigma. Anti-PAF65-b antibody was given by Y. Nakatani 33 .
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In vitro Cdk4/cyclin D1 kinase assay. GST-cyclin D1-Cdk4 complex (0142-0143-1) and GST-Rb (733-928 amino acids, 0040-0000-6) were purchased from ProQinase and 6xHis-GCN5 full length (ALX-201-280-C002) was from Enzo Life Science. Recombinant GST-GCN5 proteins (1-224 amino acids, 1-386 amino acids, 1-553 amino acids, 1-837 amino acids) were generated with pGEX-5X-2 vectors containing the corresponding sequences of mouse GCN5. pGEX-2X-GST-FoxO1 (1-300 amino acids) and FoxO1 (290-570 amino acids) were a gift from A. Banks. pGEX 4T-3 FoxO3A was purchased from Addgene deposited by M. Greenberg. GST-PGC-1a SR domain protein was generated in the laboratory 34 . For the comparison between GCN5 and Rb phosphorylation, 6 3 His-GCN5 (200 ng), GST-Rb (150 ng) and GST-cyclin D1-Cdk4 (50 ng) were used in the assay. Kinase reactions were performed in a kinase buffer (50 mM HEPES-KOH buffered at pH 7.5, 10 mM MgCl 2 ) with 20 mM ATP, 1 mM DTT and 2.5 mCi of [c-32 P]ATP from Perkin Elmer (BLU002A250UC). The reaction was incubated at 30 uC for 30 min and terminated by adding SDS sample buffer and boiling at 100 uC for 5 min. Recombinant proteins were analysed after SDS-polyacrylamide gel electrophoresis separation and silver-stained with a SilverQuest silver staining kit from Invitrogen (LC6070).
For in vitro kinase assay with immunoprecipitated cyclin D1-Cdk4 kinase from liver, lysates were extracted from pulverized livers by using Ipegal based buffer (20 mM HEPES-KOH pH 7.9, 125 mM NaCl, 1 mM EDTA, 1% Ipegal, protease inhibitor cocktail, 5 mM NaF, 5 mM glycerate-2-phosphate, 20 mM nicotinamide, 1 mM DTT and 1 mM trichostatin A). Cyclin D1-Cdk4 kinase was immunoprecipitated from 400 mg of lysates by anti-Cdk4 antibody and rabbit IgG antibody was used as a negative control. Kinase reactions were performed with 2.5 mg of recombinant Rb in a similar condition as described above except 5 mM NaF and 5 mM glycerate-2-phosphate were included in a kinase buffer. In vitro GCN5 acetyltransferase activity assay. Flag-GCN5 was immunoprecipitated with Flag-beads from nuclear lysates of U-2OS cells that were infected with GCN5 adenoviruses and treated with DMSO or 1 mM fascaplysin. Flag-GCN5 protein was eluted from the beads by rotating the lysates and beads with 3 3 FLAG peptide (Sigma F4799) at 4 uC for 2 h. The eluates were further purified using Amicon centrifugal filters (Millipore UFC5030). Following the manufacturer's instructions, the enzymatic activity was measured using a fluorimetric acetyltransferase assay kit (Active Motif 56100). Kinetic constants were calculated with the Michaelis-Menten equation based on arbitrary fluorescence units generated during 15 min reaction. Gene expression analysis. Total RNA was isolated with Trizol (Invitrogen, 15596-026). Two micrograms of RNA were used to generate complementary DNA (cDNA) with a High Capacity cDNA Reverse Transcription Kit (Applied Biosystmes, 4368813) following the manufacturer's protocol. For gene expression analysis, cDNA samples were mixed with Sybr Green qPCR mastermix (Applied Biosystem 4309155) and were analysed by a CFX384 Real-Time system from Bio-Rad. All primers and sequences are available upon request. FACS analysis for hepatocytes ploidy profile. Primary hepatocytes were isolated as described above. The cells were suspended in PBS and 1 3 10 6 cells were added drop-by-drop to pre-chilled 75% ethanol for 30 min. Ethanol was aspirated and cells were washed and re-suspended in PBS with RNase A (Invitrogen, 12091-021) at a final concentration of 70 units per millilitre. Propidium iodide (BD Biosciences, 556463) was added at a final concentration of 5 mg ml 21 to the cells and incubated for 30 min with brief vortexing in between. The samples were protected from light until analysed with BD FACSCanto II. BrdU and Ki-67 staining. Upon being killed, liver and small intestine were collected. Liver was washed in PBS briefly and the small intestine was flushed and washed with PBS. Tissues were fixed in 4% formaldehyde for 48 h and transferred to 70% ethanol before being paraffin-embedded and sectioned. Anti-BrdU antibody (B2531) was from Sigma. The antibody was run on an automated platform, Leica BOND-III. The retrieval step used Leica's ER1 solution for 30 min, and the primary antibody was incubated at 1:2,000 dilution for 30 min. A Bond Polymer Refine Detection kit was used, which included the secondary and DAB chromogen detection. The Ki-67 was also run on the BOND-III using the same detection kit. Anti-Ki-67 antibody (VP-RM04) was from Vector and was incubated at 1:250 dilution for 30 min. The retrieval solution used on the BOND-III was Leica's ER2 antigen retrieval solution and incubated for 20 min. Hyperinsulinemic-euglycemic clamp studies. Hyperinsulinemic-euglycemic clamps were performed as previously reported with minor modifications 35 . Mice were operated to implant an indwelling catheter in the right jugular vein 7 days before study. Four days before study, mice were infected with GFP or cyclin D1 T286A adenovirus by tail-vein injection. After overnight fasting, mice were infused with a fixed amount of insulin (40 mU kg 21 min 21 ) and a variable amount of 20% dextrose to maintain euglycaemia. 3-[ 3 H]glucose was included in the infusates to trace whole-body rates of glucose metabolism. Whole-body glucose uptake was determined under steady-state conditions during the final 40 min of the clamp when exogenous glucose infusion and endogenous glucose production were in equilibrium with whole-body disposal. Whole-body glucose disposal was calculated as the ratio of the 3-[ 3 H]glucose infusion rate and the specific activity of plasma glucose; hepatic glucose production represents the difference between the glucose infusion rate and whole-body uptake calculation.
Statistics. All statistics are described in figure legends. In general, for two experimental comparisons, a two-tailed unpaired Student's t-test was used. For multiple comparisons, one-way ANOVAs with Tukey, Newman-Keuls or Dunnett posttest were applied. For the glucose tolerance test, insulin tolerance test and hyperinsulinemic-euglycemic clamp, a two-way ANOVA with repeated comparison was applied. When cells were used for experiments, three replicates per treatment were chosen as an initial sample size. All n values defined in the legends refer to biological replicates unless otherwise indicated. All western blot analysis was repeated at least three times. In mice experiments requiring technical manipulations, at least seven mice were used per treatment based on our previous experiences. If technical failures such as tail-vein injection failure, inadequate intraperitoneal injection and oral gavage occurred before collection, those samples were excluded from the final analysis. Statistical significance is represented by asterisks corresponding to *P , 0.05, **P , 0.01, ***P , 0.001. h, PD 0332991 increases gluconeogenic genes when combined with GCN5 wild type (WT) overexpression, but not with GCN5 T272A/S372A (AA) mutant. GFP infected cells shown for comparison with GCN5 overexpressing cells. All cells were infected with PGC-1a adenoviruses (two-tailed unpaired t-test, n 5 6). i, j, Insulin levels measured from serum and western blot analysis of Rb and AKT using nuclear (N) and cytoplasmic (C) liver extracts from mice treated with vehicle or 150 mg kg 21 PD 0332991, shown in Fig. 2l , m (i: twotailed unpaired t-test, n 5 18/GFP, n 5 17/PD 0332991). k, Levels of cyclin D1 and Rb phosphorylation in GFP or cyclin D1 T286A tail-vein-injected mice, shown in Fig. 2n Cdk4 is dysregulated and hyperactivation of cyclin D1-Cdk4 attenuates the diabetic phenotype. a, qRT-PCR analysis of gluconeogenic and Ccnd1 gene expression changes upon fasting and re-feeding in Lepr db/1 (db/1) and Lepr db/db (db/db) mice livers (two-tailed unpaired t-test, n 5 3). b, Cyclin D1 protein is chronically elevated upon fasting and re-feeding in livers of mice fed a high-fat diet compared with control diet fed mice. Nuclear (N) and cytoplasmic (C) liver extracts were used. c, d, Phosphorylation of GCN5 is elevated upon fasting in db/db of livers of mice fed a high-fat diet (HFD) compared with respective control mice and remains insensitive to fast-re-fed transitions. Western blot analysis of GCN5 immunoprecipitated by anti-phosphoS*P (pS*P) antibody using liver extracts from mice that were tail-vein injected with adenoviruses expressing GFP or GCN5 (F, 16 h fast; R, 4 h re-fed). e, Cyclin D1 and Rb phosphorylation levels in livers from db/db mice tail-vein injected with GFP, cyclin D1 T286A or cyclin D1 K112E adenoviruses, shown in Fig. 4b, c . Nuclear and cytoplasmic liver extracts were used. f, g, Cyclin D1 T286A overexpression reduces gluconeogenic genes and glycaemia in mice fed a highfat diet (two-tailed unpaired t-test, n 5 6/GFP, n 5 7/D1 T286A). h, Cyclin D1 and Rb phosphorylation levels in livers of mice fed a high-fat diet that were tailvein injected with adenoviruses expressing GFP or cyclin D1 T286A, shown in Extended Data Fig. 4f , g. i, Overall model. Statistical significance is represented by asterisks corresponding to *P , 0.05, **P , 0.01, ***P , 0.001. Data are shown as mean 6 s.e.m.
